Sun Pharmaceutical Industries: Nifty 50 Membership and Market Performance Analysis

As of 19 Nov 2025, Sun Pharmaceutical Industries maintains a market capitalisation of approximately ₹4,20,939.33 crores, categorising it firmly within the large-cap segment. The stock trades at a price-to-earnings (P/E) ratio of 36.56, which is slightly above the Pharmaceuticals & Biotechnology industry average P/E of 33.78. This differential suggests that the market places a premium on Sun Pharma relative to its sector peers, potentially reflecting expectations of sustained earnings growth or perceived stability.

Sun Pharma’s inclusion in the Nifty 50 index is a testament to its liquidity, market capitalisation, and overall market relevance. The Nifty 50 serves as a benchmark for the Indian equity market, representing the top 50 companies by free-float market capitalisation. Membership in this index not only enhances the stock’s visibility among institutional investors but also influences passive fund flows, as many exchange-traded funds (ETFs) and index funds track the Nifty 50 composition.

Examining the stock’s recent price movement, Sun Pharmaceutical Industries recorded a day change of -0.30%, which is marginally below the Sensex’s day change of -0.15% on the same day. Over the past week, the stock’s performance at 1.30% outpaced the Sensex’s 0.09%, indicating relative short-term resilience. The one-month and three-month returns further reinforce this trend, with Sun Pharma posting gains of 4.48% and 7.24% respectively, compared to the Sensex’s 0.71% and 3.55% over the same periods.

However, when viewed over a longer horizon, Sun Pharmaceutical Industries’ performance presents a mixed picture. The stock’s year-to-date return stands at -6.90%, contrasting with the Sensex’s positive 8.20% return. Similarly, the one-year performance shows a slight decline of -1.17%, while the Sensex advanced by 8.98%. These figures suggest that despite short-term outperformance, the stock has faced headwinds in the broader market context during the current year.

On the other hand, the three-year and five-year performance metrics highlight Sun Pharma’s robust growth trajectory. Over three years, the stock has appreciated by 73.98%, nearly doubling the Sensex’s 37.11% gain. The five-year return is even more pronounced at 245.76%, significantly outpacing the Sensex’s 93.91%. This long-term outperformance underscores the company’s ability to generate shareholder value over extended periods, supported by its strategic initiatives and sectoral positioning.

Interestingly, the ten-year performance shows a return of 136.14%, which is below the Sensex’s 227.17% over the same timeframe. This divergence may reflect varying market cycles, sectoral rotations, or company-specific factors impacting returns in the earlier part of the decade.

From a technical perspective, Sun Pharmaceutical Industries is trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning often indicates a positive momentum trend, suggesting that the stock price has maintained strength relative to its recent historical levels.

The Pharmaceuticals & Biotechnology sector itself has seen mixed results in recent earnings announcements. Out of 32 stocks that declared results, 11 reported positive outcomes, 12 remained flat, and 9 posted negative results. Sun Pharma’s performance within this sectoral context is crucial, as it influences investor sentiment and relative valuation metrics.

Institutional holding patterns in Sun Pharmaceutical Industries have also seen adjustments in evaluation. As a Nifty 50 constituent, the stock attracts significant attention from mutual funds, foreign portfolio investors, and insurance companies. These institutional investors often adjust their portfolios in response to index rebalancing, sectoral outlook, and company-specific developments. Such changes can impact liquidity and price volatility, making it essential for investors to monitor these trends closely.

The benchmark status of Sun Pharma as a Nifty 50 stock further amplifies its role in the Indian equity market. Index inclusion typically results in enhanced trading volumes and greater analyst coverage, which can contribute to more efficient price discovery. Moreover, the stock’s weight in the index influences the overall sectoral representation within the benchmark, affecting passive investment flows and sectoral fund allocations.

In summary, Sun Pharmaceutical Industries remains a key player within the Pharmaceuticals & Biotechnology sector and the broader Indian equity market. Its Nifty 50 membership underscores its market significance, while its performance metrics reveal a complex interplay of short-term challenges and long-term growth potential. Investors should consider these factors alongside institutional holding trends and sectoral dynamics when analysing the stock’s prospects.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →